Pharmaceutical company Dr Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) has initiated the process for Emergency Use Authorization (EUA) of Russian COVID-19 vaccine Sputnik V in India, the company said on Friday.
As part of the review process, Dr Reddy's will present the Drugs Controller General of India (DCGI) with the safety profile of the phase 2 study and interim data from the phase 3 study, which is expected to be completed by 21 February 2021.
Dr Reddy's partnered with the Russian Direct Investment Fund (RDIF) in September 2020 to conduct clinical trials of Sputnik V and for its distribution rights in India.
The vaccine reportedly demonstrated an efficacy rate of 91.6% in the interim analysis of the phase 3 clinical trial, which included data on 19,866 volunteers in Russia who received both the first and second doses of the vaccine.
"The initiation of the EUA process will be a critical step forward for us in ensuring speedy access to the Sputnik V vaccine in India," said G V Prasad, co-chairman and managing director of Dr Reddy's.
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Hikma Pharmaceuticals USA announces USD1bn of new US investment
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder